GlassScriptPhysician profile
Tony Tsai
NPI 1548294101
$3,858.34
in general payments reported to CMS, 2019-2025
23 companies · $1,008 in 2025
The $1,008 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $713 · 2020: $193 · 2021: $165 · 2022: $213 · 2023: $770 · 2024: $798 · 2025: $1,008.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,575.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,575.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $800.68 | 2019-2025 | Susvimo, Vabysmo |
| Apellis Pharmaceuticals, INC. | $722.79 | 2023-2025 | Syfovre |
| Alcon Vision LLC | $505.47 | 2019-2025 | Rocklatan, Rhopressa, Hydrus Microstent |
| Regeneron Healthcare Solutions, INC. | $259.39 | 2019-2025 | Eylea Hd, Eylea |
| Astellas Pharma US INC | $235.93 | 2023-2025 | Izervay |
| Alimera Sciences, INC. | $200.61 | 2019-2024 | Iluvien, Yutiq |
| Immunocore Limited | $147.79 | 2025 | Kimmtrak |
| Mallinckrodt Hospital Products INC. | $143.92 | 2023 | Acthar |
| Genentech, INC. | $120.66 | 2025 | |
| Aerie Pharmaceuticals, INC. | $114.84 | 2021 | |
| Biogen, INC. | $113.45 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $90.08 | 2019-2020 | |
| Abbvie INC. | $87.29 | 2019 | |
| Notal Vision, INC. | $86.06 | 2019-2025 | Foresee Home |
| Dutch Ophthalmic, USA | $41.17 | 2023 | Tissueblue, Eva, Combined Machine |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Harrow Eye, LLC | $34.96 | 2025 | Triesence |
| Pacira Pharmaceuticals Incorporated | $32.08 | 2021 | |
| Bausch & Lomb Americas INC. | $23.12 | 2022 | |
| Ani Pharmaceuticals, INC. | $21.86 | 2025 | Iluvien |
| Neurotech Pharmaceuticals, INC. | $14.20 | 2025 | |
| Ocular Therapeutix, INC. | $13.62 | 2024 | Dextenza |
| Lumibird Medical INC. | $9.57 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tony Tsai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.